See more : Bunka Shutter Co., Ltd. (5930.T) Income Statement Analysis – Financial Results
Complete financial analysis of vTv Therapeutics Inc. (VTVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of vTv Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kobayashi Yoko Co., Ltd. (8742.T) Income Statement Analysis – Financial Results
- Shankara Building Products Limited (SHANKARA.BO) Income Statement Analysis – Financial Results
- Armada Metals Limited (AMM.AX) Income Statement Analysis – Financial Results
- Dongguan Mentech Optical & Magnetic Co., Ltd. (002902.SZ) Income Statement Analysis – Financial Results
- Tubacex, S.A. (0KD1.L) Income Statement Analysis – Financial Results
vTv Therapeutics Inc. (VTVT)
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 2.02M | 4.01M | 6.41M | 2.76M | 12.43M | 291.00K | 634.00K | 519.00K | 1.55M | 976.00K |
| Cost of Revenue | 13.60M | 92.00K | 89.00K | 11.02M | 15.12M | 23.04M | 39.64M | 45.75M | 29.58M | 18.73M | 25.43M |
| Gross Profit | -13.60M | 1.93M | 3.92M | -4.60M | -12.36M | -10.60M | -39.35M | -45.11M | -29.07M | -17.18M | -24.46M |
| Gross Profit Ratio | 0.00% | 95.44% | 97.78% | -71.73% | -447.00% | -85.26% | -13,521.99% | -7,115.77% | -5,600.19% | -1,109.10% | -2,505.94% |
| Research & Development | 13.60M | 12.36M | 13.32M | 11.02M | 15.12M | 23.04M | 39.64M | 45.75M | 29.58M | 18.73M | 25.43M |
| General & Administrative | 11.91M | 12.20M | 12.34M | 7.25M | 8.54M | 9.22M | 11.33M | 9.91M | 9.08M | 11.72M | 11.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.91M | 12.20M | 12.34M | 7.25M | 8.54M | 9.22M | 11.33M | 9.91M | 9.08M | 11.72M | 11.38M |
| Other Expenses | -13.60M | -2.67M | 4.06M | -270.00K | 828.00K | -592.00K | -190.00K | -22.00K | -2.97M | -1.13M | -534.00K |
| Operating Expenses | 11.91M | 24.56M | 25.67M | 18.27M | 23.66M | 32.26M | 50.97M | 55.65M | 38.66M | 30.45M | 36.81M |
| Cost & Expenses | 25.50M | 24.56M | 25.67M | 18.27M | 23.66M | 32.26M | 50.97M | 55.65M | 38.66M | 30.45M | 36.81M |
| Interest Income | 472.00K | 352.00K | 1.00K | 12.00K | 53.00K | 61.00K | 117.00K | 87.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.00K | 15.00K | 12.00K | 692.00K | 1.83M | 3.29M | 3.09M | 398.00K | 1.74M | 6.01M | 11.82M |
| Depreciation & Amortization | 90.00K | 92.00K | 89.00K | 94.00K | 39.00K | 218.00K | 197.00K | 265.00K | 501.00K | 864.00K | 1.09M |
| EBITDA | -25.41M | -24.77M | -17.52M | -12.02M | -19.97M | -20.14M | -50.56M | -54.69M | -38.87M | -29.23M | -35.30M |
| EBITDA Ratio | 0.00% | -1,231.81% | -439.55% | -188.81% | -723.99% | -163.70% | -17,441.58% | -8,667.98% | -7,349.13% | -1,882.44% | -3,614.86% |
| Operating Income | -25.50M | -22.54M | -21.66M | -11.85M | -20.89M | -19.82M | -50.68M | -55.02M | -38.14M | -28.90M | -35.83M |
| Operating Income Ratio | 0.00% | -1,116.95% | -540.87% | -184.78% | -755.86% | -159.43% | -17,416.49% | -8,678.23% | -7,349.13% | -1,865.53% | -3,671.41% |
| Total Other Income/Expenses | -464.00K | -2.33M | 4.05M | -950.00K | -946.00K | -3.82M | -3.17M | -333.00K | -2.97M | -7.20M | -12.37M |
| Income Before Tax | -25.97M | -24.87M | -17.62M | -12.80M | -21.84M | -23.65M | -53.85M | -55.35M | -41.11M | -36.10M | -48.20M |
| Income Before Tax Ratio | 0.00% | -1,232.56% | -439.85% | -199.59% | -790.09% | -190.16% | -18,504.12% | -8,730.76% | -7,920.42% | -2,330.60% | -4,938.83% |
| Income Tax Expense | 0.00 | 200.00K | 115.00K | -3.98M | 100.00K | 200.00K | 800.00K | -39.00M | -14.11M | 4.88M | 11.29M |
| Net Income | -20.25M | -25.07M | -17.73M | -8.83M | -21.94M | -7.91M | -16.14M | -16.35M | -27.50M | -36.10M | -48.20M |
| Net Income Ratio | 0.00% | -1,242.47% | -442.72% | -137.62% | -793.70% | -63.62% | -5,547.77% | -2,579.18% | -5,298.27% | -2,330.60% | -4,938.83% |
| EPS | -9.71 | -13.06 | -11.32 | -7.49 | -28.97 | -25.42 | -66.62 | -68.52 | -132.90 | -173.87 | -234.57 |
| EPS Diluted | -9.71 | -13.06 | -11.32 | -7.49 | -28.97 | -25.42 | -66.62 | -68.52 | -132.90 | -173.87 | -234.57 |
| Weighted Avg Shares Out | 2.08M | 1.92M | 1.57M | 1.18M | 757.30K | 311.23K | 242.33K | 238.64K | 206.91K | 207.63K | 205.49K |
| Weighted Avg Shares Out (Dil) | 2.08M | 1.92M | 1.57M | 1.18M | 757.30K | 311.23K | 242.33K | 238.64K | 206.91K | 207.63K | 205.49K |
vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%
Here's Why vTv Therapeutics (VTVT) is Poised for a Turnaround After Losing 15.2% in 4 Weeks
VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
VTVT Stock: Why It Substantially Increased Today
vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
7 Penny Stocks Waiting on The FDA for Rocket Fuel
Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround
VTv Therapeutics (VTVT) Reports Q2 Loss, Lags Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports